Table 1.
Clinical characteristics of patients diagnosed with de novo metastatic NPC.
| Characteristic | Followed by LRRT after PCT | The number of PCT cycles | ||||
|---|---|---|---|---|---|---|
| Yes | No | P value | ≤4 | >4 | P value | |
| Total | 308 | 194 | 226 | 276 | ||
| Gender | 1.000 | 0.283 | ||||
| Male | 256(83.1%) | 161(83.0%) | 183(81.0%) | 234(84.8%) | ||
| Female | 52(16.9%) | 33(17.0%) | 43(19.0%) | 42(15.2%) | ||
| Age (yr) | 0.169 | 0.180 | ||||
| ≤47 | 168(54.5%) | 93(47.9%) | 110(48.7%) | 151(54.7%) | ||
| >47 | 140(45.5%) | 101(52.1%) | 116(51.3%) | 125(45.3%) | ||
| T stage* | 0.423 | 0.684 | ||||
| T1 | 11(3.6%) | 10(5.2%) | 10(4.4%) | 11(4.0%) | ||
| T2 | 44(14.3%) | 19(9.8%) | 31(13.7%) | 32(11.6%) | ||
| T3 | 149(48.4%) | 99(51.0%) | 105(46.5%) | 143(51.8%) | ||
| T4 | 104(33.8%) | 66(34.0%) | 80(35.4%) | 90(32.6%) | ||
| N stage* | 0.333 | 0.220 | ||||
| N0 | 13(4.2%) | 3(1.5%) | 10(4.4%) | 6(2.2%) | ||
| N1 | 57(18.5%) | 32(16.5%) | 46(20.4%) | 43(15.6%) | ||
| N2 | 123(39.9%) | 79(40.7%) | 88(38.9%) | 114(41.3%) | ||
| N3 | 115(37.3%) | 80(41.2%) | 82(36.3%) | 113(40.9%) | ||
| Metastatic sites | <0.001 | <0.001 | ||||
| Bone | 166(53.9%) | 66(34.0%) | 117(51.8%) | 115(41.7%) | ||
| Lung | 37(12.0%) | 25(12.9%) | 28(12.4%) | 34(12.3%) | ||
| Liver | 23(7.5%) | 26(13.4%) | 13(5.8%) | 36(13.0%) | ||
| Other site | 32(10.4%) | 2(1.0%) | 24(10.6%) | 10(3.6%) | ||
| Multiple sites | 50(16.2%) | 75(38.7%) | 44(19.5%) | 81(29.3%) | ||
| Tumor response to PCT | <0.001 | 0.051 | ||||
| CR/PR | 213(69.2%) | 102(52.6%) | 131(58.0%) | 184(66.7%) | ||
| SD/PD | 95(30.8%) | 92(47.4%) | 95(42.0%) | 92(33.3%) | ||
| Number of PCT cycles | ||||||
| ≤4 | 156(50.6%) | 70(36.1%) | ||||
| >4 | 152(49.4%) | 124(63.9%) | ||||
| LRRT | 0.002 | |||||
| No | 70(31.0%) | 124(44.9%) | ||||
| Yes | 156(69.0%) | 152(55.1%) | ||||
PCT, palliative chemotherapy; LRRT, locoregional radiotherapy; CR, complete response; PR, partial response; PD, disease progression; SD, stable disease; TPF, cisplatin plus docetaxel plus 5-fluorouracil; TP, cisplatin plus docetaxel; PF, cisplatin plus 5-fluorouracil; GP, cisplatin plus gemcitabine.
*According to the 8th edition of the UICC/AJCC staging system.
P value was calculated with the Pearson χ2 test.